Vimarsana
Biggest News Aggregation in the World

Page 7 - Tom Graney News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tom Graney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tom Graney Today - Breaking & Trending Today

Oxurion NV: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS - Vimarsana News

Oxurion NV: Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS

Published: May 26, 2023

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special

Source: finanznachrichten.de
Related Topics:
United StatesRegion FlamandeChristopher BrinzeyMaryt ConwayTom GraneyGewinn NurCompany AnnualConway CommunicationsKreos Capital Vi United KingdomCompany Or OxurionAtlas Special OpportunitiesRegulated InformationSpecial OpportunitiesBelgian ActEuronext BrusselsCapital CommitmentSubscription AgreementKreos CapitalUnited KingdomPontifax Medison FinanceLoan Facility
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema - Vimarsana News

Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Published: May 25, 2023

                                                       ... | May 25, 2023

Source: marketscreener.com
Related Topics:
Region FlamandeUnited StatesChristopher BrinzeyMaryt ConwayTom GraneyMichael DillenCompany AnnualGlobenewswire IncConway CommunicationsData Monitoring CommitteeRegulated InformationEuronext BrusselsChief Development OfficerIndependent Data Monitoring CommitteeMacular EdemaOptical Coherence TomographyCentral Subfield ThicknessOxurion Nv Stock ExchangePress ReleaseXur Be0003846632
Oxurion NV: Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema - Vimarsana News

Oxurion NV: Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Published: May 25, 2023

Source: finanznachrichten.de
Related Topics:
Region FlamandeUnited StatesMaryt ConwayGewinn NurChristopher BrinzeyMichael DillenTom GraneyCompany AnnualData Monitoring CommitteeConway CommunicationsRegulated InformationEuronext BrusselsAndy De DeeneChief Development OfficerIndependent Data Monitoring CommitteeMacular EdemaOptical Coherence TomographyCentral Subfield Thickness
Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

Published: May 25, 2023

FinancialContent fully hosted finance channel

Source: financialcontent.com
Related Topics:
United StatesRegion FlamandeTom GraneyChristopher BrinzeyMaryt ConwayMichael DillenCompany AnnualConway CommunicationsData Monitoring CommitteeRegulated InformationEuronext BrusselsAndy De DeeneChief Development OfficerIndependent Data Monitoring CommitteeMacular EdemaOptical Coherence TomographyCentral Subfield Thickness
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema - Vimarsana News

Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Published: May 25, 2023

                                                       ... | June 11, 2023

Source: marketscreener.com
Related Topics:
United StatesRegion FlamandeMaryt ConwayTom GraneyMichael DillenChristopher BrinzeyConway CommunicationsCompany AnnualData Monitoring CommitteeRegulated InformationEuronext BrusselsAndy De DeeneChief Development OfficerIndependent Data Monitoring CommitteeMacular EdemaOptical Coherence TomographyCentral Subfield Thickness